- Repligen ( NASDAQ: RGEN ) said it had entered into a partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.
- Under the deal, Repligen will commercialize Culpeo, as well as develop future products and technologies in partnership with DRS Daylight Solutions.
- Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) and integrating these solutions into Repligen Chromatography and Filtration systems.
For further details see:
Repligen partners with DRS daylight solutions